lupus nephritis

Novel Anti-CD40 Antibody Shows Promise in Lupus Nephritis

October 6, 2025 / Research update / InnovateMed Author / lupus nephritis

TOPLINE: Iscalimab, a novel anti-CD40 monoclonal antibody, showed efficacy in lupus nephritis (LN) by reducing proteinuria at 24 weeks compared with placebo. The treatment was generally well tolerated, with most adverse events being mild to moderate. METHODOLOGY: Researchers conducted a phase 2 randomized study to evaluate the efficacy, pharmacokinetics, and safety of iscalimab vs placebo as an add-on to […]

Novel Anti-CD40 Antibody Shows Promise in Lupus Nephritis Read More »

Lupus low disease activity state attainable in lupus nephritis

August 15, 2025 / Research update / InnovateMed Author / lupus nephritis

by Elana Gotkine edited by Stephanie Baum, reviewed by Robert Egan In lupus nephritis, attainment of complete renal response (CRR)/partial renal response (PRR) and lupus low disease activity state (LLDAS) is associated with best relapse-free survival, with independent associations seen with lupus nephritis relapse risk reduction, according to a study published online July 20 in Arthritis Care & Research. Chak

Lupus low disease activity state attainable in lupus nephritis Read More »

Turning down the dial on inflammation to protect against lupus nephritis

August 5, 2025 / Kidney health, Research update / InnovateMed Author / lupus nephritis

by Kimberly McGhee, Medical University of South Carolina edited by Sadie Harley, reviewed by Andrew Zinin Credit: Pixabay/CC0 Public Domain At the time when patients with lupus, or systemic lupus erythematosus (SLE), are diagnosed, approximately 15% to 30% will already have the inflammation-caused kidney disease lupus nephritis, which compromises kidney function and can lead to kidney failure. Between

Turning down the dial on inflammation to protect against lupus nephritis Read More »

FDA approves Benlysta autoinjector for pediatric patients with active lupus nephritis

July 1, 2025 / Uncategorized / InnovateMed Author / lupus nephritis

by Lori Solomon edited by Sadie Harley, reviewed by Andrew Zinin The U.S. Food and Drug Administration has approved GSK’s autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active lupus nephritis who are receiving standard therapy. Benlysta (200 mg/mL), a B-lymphocyte stimulator-specific inhibiting monoclonal antibody, is the first and only

FDA approves Benlysta autoinjector for pediatric patients with active lupus nephritis Read More »

Novel Anti-CD40 Antibody Shows Promise in Lupus Nephritis

Lupus low disease activity state attainable in lupus nephritis

Turning down the dial on inflammation to protect against lupus nephritis

FDA approves Benlysta autoinjector for pediatric patients with active lupus nephritis

Need Help?

We are here to help.